Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00918138 · ClinicalTrials.gov registry record · Phase 3
Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg
A Phase 3 study of Type 2 Diabetes, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 219
- Enrollment target
- 20
- Study locations
NCT00918138 is a Phase 3 study of Type 2 Diabetes that has completed, run by AstraZeneca. The registered enrollment target is 219 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00918138, a Phase 3 study of Type 2 Diabetes, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 219 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to compare effect of Saxagliptin as add-on to Metformin on 24-hour mean weighted glucose (MWG) to the effect of uptitrating Metformin in subjects with T2DM inadequately controlled on metformin alone.
Conditions Studied
Interventions
- DRUG Saxagliptin
- DRUG Metformin XR
- DRUG Placebo matching Metformin XR
- DRUG Placebo matching Saxagliptin
Study Locations (20)
Other
- Local Institution - Beersheba
- Local Institution - Holon
- Local Institution - Kfar Saba
- Local Institution - Safed
Florida
- Clinical Research Of South Florida - Coral Gables
- Palm Springs Research Institute - Hialeah
- Healthcare Clinical Data, Inc. - North Miami
California
- Pacific Sleep Medicine Services (Avastra Clinical Trials) - Redlands
- Orange County Research Center - Tustin
Buenos Aires
- Local Institution - Buenos Aires
- Local Institution - Capital Federal
Durango
- Local Institution - Durango
- Local Institution - Durango
Arizona
- Dedicated Phase I, Inc. - Phoenix
Georgia
- River Birch Research Alliance, Llc - Blue Ridge
Michigan
- Jasper Clinic, Inc. - Kalamazoo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00918138
The ClinicalTrials.gov registry entry for NCT00918138 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (80% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 4 interventions - of which Saxagliptin is the first listed.
NCT00918138 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Florida, California.
Frequently Asked Questions
What is clinical trial NCT00918138 about?
NCT00918138 is a clinical study titled "Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg". The purpose of this study was to compare effect of Saxagliptin as add-on to Metformin on 24-hour mean weighted glucose (MWG) to the effect of uptitrating Metformin in subjects with T2DM inadequately controlled on metformin alone.
What is the current status of trial NCT00918138?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 219 participants. The study started on 2009-08. Estimated completion is 2010-05.
What conditions does trial NCT00918138 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT00918138?
The interventions under investigation include: Saxagliptin (DRUG), Metformin XR (DRUG), Placebo matching Metformin XR (DRUG), Placebo matching Saxagliptin (DRUG).
Who is sponsoring clinical trial NCT00918138?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00918138 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.